A new ESC analysis reveals that measured weight loss does not fully explain semaglutide's cardiovascular benefits in the SELECT trial. Here is what it means.
On September 24, 2026, the European Society of Cardiology published new findings regarding the cardiovascular effects of semaglutide. The organization reported on a new mediation analysis of the SELECT trial. This analysis examined whether the cardiovascular benefits of the medication could be explained by changes in weight. It also looked at several other measured risk factors to understand the underlying mechanisms.
These findings arrive at a critical time for patients evaluating their treatment plans. The scientific conversation is moving away from treating scale weight as the only meaningful endpoint. Clinicians are increasingly focusing on cardiometabolic outcomes to measure true progress. This shift is crucial for understanding the complete picture of metabolic health.
The ESC press release identified Novo Nordisk as the funder of this study. The release also disclosed financial relationships involving the study lead and other investigators. While this funding structure is common in clinical research, it remains relevant context. It highlights the ongoing need for independent replication of these findings.
The researchers designed the mediation analysis to understand how semaglutide lowers cardiovascular risk. They examined whether changes in body weight and waist circumference statistically explained the lower cardiovascular-event rate. The team also evaluated blood pressure and cholesterol alongside diabetes-related markers. They further measured systemic inflammation and kidney function during the detailed analysis.
The investigators assessed these potential mediators individually to see their isolated impacts. They also tested them in various subsets and grouped them all together. The results showed that no combination explained more than half of the cardiovascular risk reduction. This suggests that the medication operates through pathways that standard clinical measurements do not fully capture.
Study lead Professor Helen Colhoun of the University of Edinburgh addressed these findings directly. She stated that the analyses could not fully attribute the cardiovascular effects to known risk factors with absolute certainty. The exact biological mechanisms preventing cardiovascular disease remain partially unidentified. Colhoun proposed that anti-inflammatory effects not fully captured by the study measurements might play a role.
She also suggested the medication could have direct effects on heart muscle or the lining of blood vessels. These potential direct effects could explain the remaining cardiovascular protection. Because of these findings, Colhoun noted that semaglutide should be considered a cardiovascular-disease-reduction drug. It should no longer be viewed exclusively as a weight-loss medication.
Some media headlines suggest that semaglutide works entirely independently of weight loss. That interpretation misses the actual scientific nuance detailed in the ESC report. The research simply found that measured risk-factor changes did not fully explain the observed outcomes. It did not conclude that weight reduction made no contribution to heart health.
An unexplained portion of a statistical model does not automatically prove a new biological mechanism. This unexplained variance might reflect unmeasured biological pathways or imperfect measurement tools. It could also stem from statistical assumptions or residual confounding factors within the trial data. The investigators themselves cautioned that their findings rely on estimated risks rather than absolute certainties.
One of the most common mistakes I see in adults over forty is focusing solely on the scale. People would celebrate rapid weight loss, only to find their energy plummeted and their metabolism slowed. They were losing muscle instead of just fat. Shifting the conversation from generic weight loss to body composition and strength training has been one of the most impactful changes we have championed.
This philosophy directly applies to how we should view these new cardiovascular findings. We must look at the complete biological ecosystem rather than a single metric. The ESC reported that data collection occurred partly during the COVID-19 pandemic. Some participants may have also lost weight for reasons other than taking semaglutide.
Frailty is a particularly important example of this complication in clinical data. Unintentional weight loss associated with frailty may actually signal poorer health and higher cardiovascular risk. This makes the relationship between weight change and health outcomes very difficult to interpret accurately. It also reinforces why utilizing effective methods for tracking body composition is so vital.
Understanding these new findings requires looking back at the original SELECT trial parameters. The study enrolled 17,604 adults who were at least 45 years old. These participants all had established cardiovascular disease and a body-mass index of at least 27 kg/m². Notably, none of the participants had a history of diabetes.
The original SELECT results demonstrated a clear difference in major adverse cardiovascular events. These critical events included cardiovascular death, nonfatal heart attacks, and nonfatal strokes. The events occurred in 6.5 percent of the semaglutide-treated participants. In contrast, the placebo group experienced an event rate of 8.0 percent.
This difference corresponds to a hazard ratio of 0.80 for the treatment group. It represents a 20 percent relative risk reduction compared to the placebo. However, it is crucial to understand that a 20 percent relative risk reduction is not a 20-percentage-point absolute reduction. The absolute difference between the two groups was 1.5 percentage points.
The U.S. Food and Drug Administration approved Wegovy in 2024 to reduce the risk of cardiovascular death. The approval also targeted heart attacks and strokes in adults with cardiovascular disease and overweight or obesity. The SELECT results were important because they demonstrated a cardiovascular benefit without the presence of diabetes.
A 2026 review of GLP-1 receptor agonists highlighted the complex nature of these metabolic treatments. The review described the relationship between weight loss and cardiovascular benefit as highly nuanced. This relationship is neither linear nor uniform across different clinical populations. The way a patient responds can vary significantly based on their unique medical history.
The review specifically noted that the SELECT trial demonstrated cardiovascular-event reduction in patients without diabetes. In contrast, other clinical trials have shown different patterns of health improvements. These other studies have linked greater weight loss to improvements in physical symptoms or daily function. They have not necessarily linked that weight loss to superior prevention of major cardiovascular events.
This distinction is critical for understanding the evolving landscape of metabolic health treatments. The broader research direction is clearly moving toward a more comprehensive view of cardiometabolic outcomes. These broader outcomes include blood pressure, glycemic markers, kidney measures, inflammation, and lipids. Evaluating these diverse endpoints provides a much more accurate picture of a patient's overall health status.
These clinical observations carry significant practical implications for anyone using weight-management medication. The analysis cannot establish that a person who loses little weight will receive the same cardiovascular benefit. The findings also apply specifically to a higher-risk population with established cardiovascular disease. They should not be automatically generalized to every adult using semaglutide.
At WeightRestart, we emphasize a body-neutral approach that focuses on metabolic health rather than aesthetics. For someone using these treatments, the scale is only one possible outcome measure to track. Discussions with a clinician should also include blood pressure, cholesterol, and blood-glucose markers. Patients should monitor kidney health, waist circumference, physical function, and their personal cardiovascular history.
A plateau on the scale should not automatically be interpreted as proof that treatment has failed. The SELECT mediation analysis confirms that measured weight and cardiometabolic changes do not fully account for the benefits. However, assuming that weight change is entirely unimportant is also an unsafe conclusion. Our goal is to translate this complex clinical research into simple, actionable steps for everyday life.
People should avoid changing their dose or stopping treatment solely based on this single study. Semaglutide should never be treated as a substitute for other necessary cardiovascular care. We always encourage navigating the reality of emerging weight-loss medications through clear, evidence-based conversations. Your healthcare provider can help you manage your entire ecosystem of weight management safely.
Understanding why GLP-1 weight-loss efficacy varies helps patients maintain realistic expectations. Health progress should always be assessed using several meaningful outcomes rather than scale weight alone. This comprehensive approach aligns with our core mission of promoting sustainable weight loss and metabolic health.
Future clinical trials will need to specifically isolate and test the proposed biological mechanisms. Researchers must investigate the potential direct effects on heart muscle and vascular linings to confirm Colhoun's theories. Until then, these findings support having broader, more comprehensive conversations with your healthcare provider. The focus must remain on comprehensive cardiometabolic health rather than searching for isolated, single-variable solutions.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
